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Background: A new modality is necessary to prevent recurrence of superficial bladder cancer after complete
transurethral resection because of the high recurrence rate even with current prophylaxis protocols.
Methods: In order to analyze the predictive value of cyclooxygenase-2 (COX-2) expression and tumor infiltrating
lymphocytes (TILs) in recurrence of this disease tumor specimens from 127 patients with solitary papillary
non-muscle invasive bladder cancer (NMIBC), 78 with recurrent disease and 49 without recurrence during follow up
of minimum 5 years, were retrieved for tissue microarrays construction and immunohistochemical analysis. COX-2
expression was scored according to Allred’s scoring protocol, while presence of TILs was categorized as absent (no)
or present (yes) on whole tissue sections.
Results: COX-2 immunoreactivity was presented in 70 (71%), weak in 16% and strong in 55% of cases, while 29
(29%) tumors were negative. TILs were present in 64 (58%) NMIBC, while 44 cases (41%) did not reveal
mononuclear infiltration in tumoral stroma. Statistical analysis demonstrated a higher proportion of patients with
recurrence in the group with the COX-2 score 0, and lower in the group with score 2 (p=0.0001, p=0.0101,
respectively). In addition, a higher proportion of recurrent patients in the group with no TILs, and lower proportion
in the group with TILs were found (p=0.009, p=0.009, respectively). Univariate and multivariate analysis revealed
overexpression of COX-2 and presence of TILs as negative predictors.
Conclusion: Patients with lower COX-2 expression and absence of TILs in NMIBC need to be followed up more
vigorously and probably selected for adjuvant therapy.
Virtual slide: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1411318819790406
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Urinary bladder cancer (UBC), on the average, includes
2% of all the malignant diseases with male-to-female
ratio being about 4:1. The incidence of UBC increases
with age [1]. The mortality from transitional cell carcin-
oma (TCC) of the urinary bladder increases significantly
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reproduction in any medium, provided the orApproximately 75-85% of patients present with a non-
muscle invasive bladder carcinoma (stages pTa, pT1,
pTis). Despite the same category this is a very heteroge-
neous group of tumors with various biological out-
comes. The main clinical feature of UBC is a high
percentage of recurrence [2]. Carcinoma of the urinary
bladder is the only malignant neoplasm for which im-
munotherapy is often included as part of standard care.
Intravesical instillations of Bacille Calmette–Guerin
(BCG) has been demonstrated to reduce the recurrence
rate and the risk of progression to muscle-invasive dis-
ease in patients with carcinoma in situ (pTis), as well as
non-muscle-invasive urothelial carcinomas [3,4]. BCGtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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complete response rates for carcinoma in situ and small
residual tumors, respectively [5]. Unfortunately, a signifi-
cant percentage of patients will fail initial BCG therapy.
These patients would have much more benefit if they were
oriented early to other therapeutic approaches. In
addition, another 30% to 50% of BCG responders will de-
velop recurrent tumors within 5 years [6,7].
In fact, 70% of patients treated with transurethral re-
section (TUR) experience a relapse of the underlying
disease and 15-25% of patients will progress over time to
muscle-invasive cancer [2]. Although some prognostic
variables have been shown to predict recurrence and can
be used to identify patients who require adjuvant ther-
apy after TUR, additional reliable markers for disease
progression and recurrence are needed [8-10].
Standard prognostic factors like histological grading
are limited in predicting possible recurrence of the dis-
ease. So, understanding of molecular processes that
could reflect individual biological potential and clinical
behavior is important. For that purpose, various biomar-
kers have been investigated since they have potential in
decoding unique biological features in identifying
patients with high risk of progression after the local
treatment, as well as in more reliable prognosis and
treatment of UBC [11]. In the present study the
cyclooxygenase-2 (COX-2) was investigated. Beside
prostaglandin G/H synthases and COX-1 it is one of the
key enzymes in the synthesis of prostaglandins from ara-
chidonic acid. COX-2 is not expressed in most tissue
under normal conditions, but expression is rapidly
induced by growth factors or agents that cause tissue ir-
ritation or inflammation [12]. COX-2 is expressed in
many solid as well as hematological malignancies [13]
where prostaglandins have been reported to increase
proliferation, enhance angiogenesis, promote invasion,
and inhibit apoptosis and differentiation, thus participat-
ing in carcinogenesis through various mechanisms
[13,14]. There is evidence that COX-2 expression and
activity is also important in the development of UBC
[15,16].
To determine if COX-2 overexpression could be caus-
ally related to recurrence of superficial UBC the present
study was designed with pathologically homogenous
group of solitary papillary non-muscle invasive bladder
cancer (NMIBC) presented in patients according to de-
velopment of the recurrent disease. More specifically,
the aim was to assess and compare the COX-2 expres-
sion between the patients with and without recurrence
of disease and, moreover, to analyze association between
COX-2 expression and tumor infiltrating lymphocytes
(TILs). We hypothesize that such investigation can be
used to predict recurrence and help identify patients
who require adjuvant treatment.Materials and methods
Clinicopathological data
The tumor specimens analyzed in this study were
obtained from a total of 127 patients with solitary papil-
lary NMIBC treated with initial transurethral resection
(TUR), as a standard procedure at the Department of
Urology, Rijeka University Hospital Center in Rijeka, be-
tween 1996 and 2006. None of the patients received ad-
juvant chemotherapy or immunotherapy or any other
medical intervention after the initial TUR. All patients
with multiple tumors and patients with a solid or flat as-
pect of the tumor were excluded from this study. The
study was approved by the University of Rijeka Ethics
Committee.
All the sections were reviewed to confirm the original
diagnosis and were staged according to the 2002 American
Joint Committee on Cancer guidelines [17] and graded
according to the 2004 World Health Organization classifi-
cation system [18] by an expert urologic pathologist. All
the tumors were classified as papillary urothelial neoplasm
of low malignant potential (PUNLMP) or low-grade papil-
lary urothelial carcinoma (LGPUC). Clinicopathologic data
were obtained from patient medical records and from the
files kept at the Department of Pathology, Rijeka University
School of Medicine. Based on disease recurrence, patients
were divided in two groups: patients who developed recur-
rent disease during the first five post-operative years
(N=78) and patients without recurrent disease during a
follow-up of minimum 5 years (N=49). The follow-up of
patients was subsequently scheduled at control cystoscopy
every 3 months for the first two years after TUR, and after
that biannually. Recurrence was defined as a written de-
scription of a recurrent tumor at any control cystoscopy 6
months after the operation, localized away from the pri-
mary tumor bed and the area of the initial resection. By
this procedure protocol we wanted to exclude all possible
residual tumor masses.
Hematoxylin and eosin stained tumor sections were
used in order to evaluate the presence of inflammatory
cells and to mark the areas with the most pronounced
inflammatory infiltrate for construction of tissue micro-
arrays. Positive inflammatory cells were semi quantita-
tively graded and presence of TILs was categorized as
absent (no) or present (yes) as shown in Figure 1.
Tissue microarray construction (TMA)
Paraffin blocks were available for all 127 cases, and
TMAs were constructed by using a manual tissue
arrayer (Alphelys, Plaisir, France). Three tissue cores,
each 1 mm in diameter, were placed into a recipient par-
affin block. Normal liver tissue was used for orientation.
Cores were spaced at intervals of 0.5 mm in the x- and
y-axes. One section from each TMA block was stained
with hematoxylin and eosin to confirm the presence of
Figure 1 Urothelial tumors (hemalaun-eosin) with strong (A) and moderate (B) mononuclear inflammatory infiltrates in lamina propria
(*) predominantly composed of lymphocytes.
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for immunohistochemical staining. Three to four μm
thick sections were placed on adhesive glass slides (Ca-
pillary Gap Microscope Slides, 75 μm, Code S2024,
DakoCytomation, Glostrup, Denmark), left to dry in
oven at 55°C overnight, deparaffinized and rehydrated.
Immunohistochemistry and scoring
Tumor samples were processed for immunohistological
analysis in a Dako Autostainer Plus (DakoCytomation
Colorado Inc, Fort Collins, CO, USA) according to the
manufacturer’s protocol using Envision peroxidase pro-
cedure (ChemMate TM Envision HRP detection kit
K5007, DakoCytomation, Glostrup, Denmark).
The sections were incubated with the primary anti-
bodies, anti-COX-2 mouse monoclonal antibody (clone
CX-294, code M3617, DAKO, Denmark), dilution range
1:100. The immune reaction was amplified using the ap-
propriate secondary antibody and the Streptavidin–Bio-
tin–Peroxidase HRP complex (code K5001, DAKO,
Denmark). Sections were then developed using 3,30-dia-
minobenzidine tetrahydrochloride chromogen (DAB,
code K5001, DAKO, Denmark), under microscope con-
trol. The sections were counterstained with Mayer’s
Hematoxylin. Quality control performed by external and
internal negative and positive controls was necessary to
monitor the accuracy of tissue processing, staining pro-
cedures and reagents effectiveness. The primary anti-
body specificity sought to be assessed by their negative
controls.
COX-2 immunohistochemical expression was quanti-
fied and scored by assessing a proportion of percentage
as an intensity score according to Allred’s scoring proto-
col [19]. The assigned proportion score represented the
estimated proportion of positive-staining cells (0, none;
1, <1/100; 2, 1/100 to 1/10; 3, 1/10 to 1/3; 4, 1/3; to 2/3;
and 5, >2/3). The intensity score assigned represented
the average intensity of positive cells (0, none; 1, weak;
2, intermediate; and 3, strong). The proportion and in-
tensity scores were combined to obtain a total score,
which ranged from 0 to 8. Total score 0–2 was assessedas negative (0), score 3–5 was assessed as weak positive
(1) and 6–8 as strong positive (2). All slides were scored
by investigator who was blinded to patient clinical
information.
For the purpose of further statistical analysis, the mean
values of immunohistochemical staining of all three tis-
sue microarrays were used.
Statistical analysis
Statistical analysis was performed using MedCalc for
Windows, version 12.3.0.0 (MedCalc Software, Mariakerke,
Belgium). In the first part of the work the classical de-
scriptive methods were used as well as the Chi-square
test for the comparison of proportions. Mann–Whitney
test was used to compare the medians. The method of
logistic regression was used in order to compute the
odds ratio for predictors of recurrence in univariate and
multivariate manner. The AUC value was used to evaluate
the quality of predictive model. The significance level in
all tests was 0.05.
Results
Clinicopathological characteristics and
immunhistochemical findings in NMIBC
Clinicopathological characteristics of 127 patients with
solitary, papillary NMIBC unrolled in the present study
are summarized in Table 1. All clinical details along with
adequate tumor samples, at the time of diagnosis and in
follow up period, were available for all patients. None of
the patients was lost to follow up. The median age at diag-
nosis for the patient cohort was 73 years (range 41–87),
with a male to female ratio of 3.3:1, and a median
follow up period of 37 months (range 6–155). Tumors
divided according to their size in ≤3 or >3 cm, accord-
ing to their pathology in groups of papillary urothelial
neoplasms of low malignant potential (PUNLMP) and
low grade papillary urothelial carcinoma (LGPUC), and
according to their stage in Ta and T1 were nearly
equally distributed.
Immunohistochemical analysis revealed COX-2 expres-
sion predominantly granular localized to the cytoplasm of
Table 1 Clinical features of patients with non-muscle
invasive bladder carcinoma along with pathological and
immunohistochemical characteristics of the resected
tumors




Age (years, median, range) 73 (41–87)
Tumor size: Cases (%)
> 3 cm 59 (46)




Disease stage Cases (%)
Ta 54 (46%)
T1 64 (54%)
Median follow-up (months) 37







Note: †PUNLMP indicates papillary urothelial neoplasm of low malignant
potential; ‡LGPUC, low-grade papillary urothelial carcinoma; *TILs, tumor-
infiltrating lymphocytes.
Figure 2 Immunohistochemical staining for COX-2 on tissue microarr
magnification representative cases demonstrate tumor cells with strong (B
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cases immunoreactivity was detected in endothelial cells
within the tumor. Low intensity staining was also
observed in smooth muscle tissue in some sections. There
was noticeable heterogeneity in the intensity and percent-
age of COX-2 positive cells within the tumor tissues. Posi-
tive COX-2 immunoreactivity scored according to Allred
was presented in 70 (71%) while 29 (29%) tumors were
negative. Among positive tumors 16 (16%) show weak and
54 (55%) strong immunostaining. Representative cases of
tumors with moderate and strong COX-2 staining are pre-
sented in Figure 2.
Tumor infiltrating lymphocytes as shown in Figure 1
were presented in majority (64; 59%) of cases, while 44
cases (41%) did not reveal mononuclear infiltration in
tumoral stroma.
COX-2 expression and TIL in correlation with recurrence
of disease
Main objectives of the present study were to examine
possible association between COX-2 expression and
TILs with regard to recurrence of disease, as well as
their mutual relationship which revealed no significant
association (p=0.892).
Clinicopathological parameters included in the above
mentioned analysis are presented in Table 2. As it can
be seen among the examined parameters pathology and
disease stages were different between recurrent and non
recurrent disease. In particular, PUNLMP was more pre-
sented (61%) among the non-recurrent disease in oppos-
ite to LGPUC that was more frequently present (62%) in
the recurrent group (p=0.0258, p=0.0258, respectively).ays of urothelial tumors (A, magnification x20). On higher
), moderate (C) and weak (D) staining (magnification x100).
Table 2 Clinicopathologic characteristics, COX-2
expression and TIL in comparison to recurrence of
non-muscle invasive bladder carcinoma
Recurrent disease
N=127 Yes (n=78) No (n=49) P-value
Gender Cases (%) Cases (%)
Male 58 (74) 36 (73) 0.8834
Female 20 (26) 13 (27)
Age (years, median, range) 71 (41 – 87) 67 (54 – 78)
Tumor size: Cases (%) Cases (%)
> 3 cm 40 (51) 19 (39) 0.1104
≤ 3 cm 38 (49) 30 (61)
Pathology: Cases (%) Cases (%)
PUNLMP† 26 (38) 28 (61) 0.0258
LGPUC ‡ 43 (62) 18 (39)
Disease stage Cases (%) Cases (%)
Ta 26 (37) 28 (61) 0,0182
T1 46 (63) 18 (39)
Median follow-up (months) 13 75
COX-2 score Cases (%) Cases (%)
0 27 (45) 2 (5) 0.0001
1 7 (12) 9 (23) 0.2196
2 26 (43) 28 (72) 0.0101
TILs* Cases (%) Cases (%)
No 32 (53) 12 (26) 0.009
Yes 29 (47) 35 (74)
Note: †PUNLMP indicates papillary urothelial neoplasm of low malignant
potential; ‡LGPUC, low-grade papillary urothelial carcinoma; * tumor-
infiltrating lymphocytes.
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with recurrence in stage T1 (63%), while those patients
without recurrent disease were in stage Ta (61%)
(p=0.018).
Moreover, statistical analysis demonstrated a difference
in tumors COX-2 expression between the analyzed
groups, e.g. between recurrent and non-recurrent
patients. Possibly, due to small sample size in the group
with the score 1 no significant difference was found be-
tween recurrent and non-recurrent patients (p=0.2196).
In the group with the score 0 and the group with the
score 2 there was a significant difference in the propor-
tion of patients with and without recurrence (p=0.0001,
p=0.0101, respectively). From these results we can ex-
pect that lower score is predictor of recurrence, since
there is higher proportion of recurrent patients with
score 0 and lower proportion of recurrent patients with
score 2.
A significant difference between the recurrent and non-
recurrent patients in both groups, with absent and present
TILs was also found (p=0.009, p=0.009, respectively).More precisely, higher proportion of recurrent patients in
the group with no TILs and lower proportion in the group
with TILs were found. Therefore, we can expect the ab-
sence of TILs to be the predictor of recurrence.
Univariate and multivariate analysis of prediction of
recurrence
Univariate and multivariate analysis of the influence of
COX-2 expression, TILs, tumor size and disease stage
on prediction of recurrence (PR) are shown in Table 3.
The odds ratio for each predictor was computed using
the method of logistic regression. As we can see the
tumor size is not the significant predictor in univariate,
as well as is in multivariate manner. Disease stage is in
both analysis significant and positive predictor, which
means that the odds for a recurrence in cases with stage
1 are 2.39 times higher than in cases with stage 0. In
both manners the TILs and COX-2 are negative predic-
tors. The positive change in score for COX-2 (score
higher for 1) produces 0.36 times lower risk, or that the
odd for not getting a recurrence is 1/0.36=2.77 times
higher. The TILs is also significant negative predictor of
recurrence with OR 0.31 in univariate manner and 0.23
in multivariate analysis. The AUC value as a classifica-
tion parameter which gives us the quality of predictive
model was used. In our case we have the AUC 0.875
which means that our model has very high discriminat-
ing power.
Discussion
There is large evidence implicating COX-2 activity in
the development of UBC. Yet, the results obtained in the
present study demonstrated that low COX-2 instead of
high COX-2 score could predict the recurrence of
NMIBC. These results open many questions related to
the methodology used in various studies, as well as the
complexity in understanding the role of different bio-
logical markers in tumorigenesis.
In the present study we used TMA instead of whole tis-
sue section for immunohistochemical analysis. Gudjonsson
et al. in their study analyzed COX-2 among different
markers on TMA and they found that proteins assessed
had no predictive value for recurrences of Ta bladder can-
cer (BC) [20]. The concerns have been raised by the
authors regarding the methodology and generalization of
results obtained with TMA in immunohistochemical ana-
lysis. Even so we believe that conclusion was made despite
the facts that relatively small number of patients (N=52)
was analyzed. TMA construction was done with at least
three 0.6 mm punch cores and specimens were heteroge-
neous, including single and multifocal tumors. In order to
minimize these problems the present study was conducted
on relatively larger number of the patients (N=127), with
only single tumor at the time of diagnosis, and with
Table 3 Predictors of recurrence: univariate and multivariate analyses
Predictor Univariate Multivariate
OR 95% CI P-value AUC OR 95% CI P-value
Tumor size 1.69 [0.82; 3.49] 0.1541 0.565 1.71 [0.62; 4.69] 0.3007
Disease stage 2.39 [1.15; 4.98] 0.0194 0.607 3.29 [1.18; 9.19] 0.0228
TILs 0.60 [0.40; 0.89] 0.0122 0.651 0.49 [0.29; 0.84] 0.0092
COX-2 0.36 [0.20; 0.63] 0.0004 0.691 0.27 [0.14; 0.53] 0.0002
p<0.0001, AUC=0.875 (95%CI 0.747; 0.907)
Note: OR= Odds ratio; CI = Confidence interval; AUC = Area under the curve; TILs = tumor-infiltrating lymphocytes.
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selected for TMA construction. Nevertheless, the obtained
results indicate that different methodology and also di-
verse scoring system for protein expression could be the
reason for different results and conclusion made in differ-
ent papers.
Previous studies have been conducted mostly on het-
erogeneous groups of patients with superficial and inva-
sive UBC. One of the first papers in which the
expression of COX-1 and COX-2 were analyzed in
human invasive TCC of the urinary bladder samples was
by Mohammed and coworkers [21]. COX-2 was not
expressed in normal urinary bladder samples but was
detected in invasive TCC, noninvasive TCC samples, and
in cases of carcinoma in situ. Authors concluded that
COX-2 may play a role in BC and support further study
of COX-2 inhibitors as potential antitumor agents in
human BC. After this study several other ones showed
significant increase of COX-2 expression with advancing
tumor grade and T stages of the disease [22,23], and not
only with disease progression but also with BC specific
survival [24].
Opposite to the role of COX-2 in tumor progression
there are also studies where COX-2 expression was not
associated with primary tumor stage, lymph node status,
histological grading, overall and disease-free survival
[25]. Wulfing et al. also did not find COX-2 expression
associated with TNM staging, histological grading, over-
all or disease free survival, but a significant relation to
the histological subtype (transitional vs. squamous cell
carcinoma) was present [26]. Subgroup of chemotherapy
patients demonstrated a significant correlation of strong
COX-2 expression with worse overall survival time. The
authors concluded that further experimental and clinical
studies were needed to elucidate if COX-2 inhibition can
serve as an additive therapy to chemotherapy of BC.
There are also several studies analyzing COX-2 expres-
sion only in NMIBC. In the CIS group, COX-2 expression
was significantly associated with disease recurrence and
progression, but not with BC related survival (as in our
analysis, data not shown), while in the stage T1 the TCC
COX-2 expression was not associated with clinical or
pathological parameters or clinical outcome [27]. Kim andcoworkers in their study selected only T1G3 TCC who
had undergone complete TUR [28]. In that case COX-2
expression was statistically significant in predicting both
recurrence and disease progression, while patients’ age,
shape and multiplicity of tumors were not significantly
predictive. Thus patients, according to authors’ conclu-
sion, with COX-2 positive superficial BC may need to be
followed up more vigorously. In the paper of Okajima
et al. with only 5 and 6 samples of superficial BC cases
with and without recurrence, respectively, after TUR,
more COX-2 protein samples in the cases with recurrence
than in cases without recurrence were found [29]. Even
though the number of cases examined is small, as the
authors stated, this result supports their hypothesis that
COX-2 contributes to superficial BC recurrence, thus se-
lective COX-2 inhibitors can be a candidate chemo pre-
ventive agents for reoccurrence.
Our results differ from the above mentioned because
loss of COX-2 was a predictive marker of tumor recur-
rence. We believe this can be explained by very complex,
even different role of this enzyme during tumorigenesis.
There is no doubt that COX-2 expression is sequentially
up-regulated from normal to chronic cystitis and to ma-
lignant changes [30]. Also there are evidence that COX-
2 is involved in angiogenesis in BC, as described in the
paper where COX-2 promoted vessel proliferation in the
tumor zone of pTa/pT1 NMIBC [31]. Moreover, COX-2
is probably up-regulated during tumor progression, as
mentioned above, but we believe its role in initial stage
is very complex. We hypothesize that, in the initial
tumor stage, COX-2 is probably associated with host im-
munological/inflammatory response and, as such, it
could be a marker of sufficient anti-tumor response
while loss of COX-2 expression may be indication for
the selection of patients for additional immunotherapy.
This supposition is also supported by our finding that
absence of TILs became the predictor of recurrence. In
our study we could not find the association between
COX-2 and TILs although there is study by Himly and
coworkers in which the association between COX-2 ex-
pression and T lymphocyte subsets, CD4+ and CD8+,
was confirmed [23]. However, our previous work con-
firmed the proportion of CD4+ cells and Granzyme B+
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of patients [32].
Conclusion
Although further studies are necessary to fully elucidate
the mechanism involved, the present study showed that
higher COX-2 expression and present TILs resulted as a
negative predictor of recurrence in NMIBC. On the
other hand, patients with lower value of both analyzed
parameters should be probably selected for adjuvant
therapy.
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